SCHEMBL5451213

SCHEMBL5451213

CCC1CCNC(=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13575606 1.00
SCHEMBL2526110 0.88 HTT (0.41)
SCHEMBL5554585 0.84 NOS1 (0.31)
SCHEMBL5502631 0.83 CYP1A2 (0.37)
SCHEMBL8299815 0.83
SCHEMBL5155505 0.82 MEN1 (0.33)
SCHEMBL4414565 0.81 CRBN (0.40)
SCHEMBL5554582 0.80
SCHEMBL26718370 0.80 CYP1A2 (0.46)
SCHEMBL26064924 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4212025-A1 MOUTH-COATING FEEL ENHANCER AJINOMOTO CO., INC. (JP) 2023-07-19 EP claimed
US-20230210153-A1 MOUTH-COATING FEEL ENHANCER AJINOMOTO CO., INC. (JP) 2023-07-06 US claimed
CN-1662506-A Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor ISRAEL INST BIOLOG RES (IL) 2005-08-31 CN claimed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
US-12479830-B2 Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2025-11-25 US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 US disclosed
US-12264154-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-04-01 US disclosed
CN-114502549-B Homopiperazinyl and homopiperidinyl quinazolin-4 (3H) -one derivatives having multimodal activity against pain 埃斯特韦制药股份公司 2024-10-25 CN disclosed
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
EP-0724570-B1 AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS SEARLE & CO (US) 1999-03-03 EP disclosed
EP-0897912-A1 Amidino derivatives useful as nitric oxide synthase inhibitors G.D. SEARLE & CO. (US) 1999-02-24 EP disclosed
US-5854234-A Amidino dervatives useful as nitric oxide synthase inhibitors G. D. SEARLE & CO. (US) 1998-12-29 US disclosed
EP-0724570-A1 AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1996-08-07 EP disclosed
WO-1995011231-A1 AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G. D. SEARLE & CO. (US) 1995-04-27 WO disclosed
US-4058462-A System for sustained release of phenolic material from porous granules of insoluble polymeric phenolic complexes GAF CORPORATION (US) 1977-11-15 US disclosed
US-3985540-A Metal complexes of hydroxyquinoline and polymeric porous granules GAF CORPORATION (US) 1976-10-12 US disclosed
US-3970606-A N-vinyl lactam interpolymers useful as thickening agents GAF CORPORATION (US) 1976-07-20 US disclosed
US-3954682-A GRANULES OR BEADS GAF CORPORATION (US) 1976-05-04 US disclosed